You are here: Industry Insights > Dupilumab

News List

Breakthrough Therapy for Type 2 Immune Indications: the Ten Billion dollars drug Dupilumab will be marketed in China PharmaSources/1℃
June 19, 2020
Sanofi explained in detail the mechanism of action of Dupilumab and its clinical benefit in type 2 immune indications at a recent R&D conference.
New Asthma Drug, Dupilumab (Dupixent) Helps Kids, But Price Tag Is High Drugs
December 10, 2021
Children with hard-to-control asthma may get relief from adding an injectable antibody drug to their standard treatment, a clinical trial has found.
Sanofi’s Dupixent 'rapidly' improves lung function in children pharmatimes
May 18, 2021
Sanofi’s Dupixent significantly reduced severe asthma attacks and rapidly improved lung function in children aged six to 11 years old with uncontrolled moderate-to-severe asthma, according to detailed results from a Phase III trial.
FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis drugs
June 27, 2019
FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis.
Sanofi, Regeneron’s Dupixent shines in rhinosinusitis with nasal polyps trials pharmatimes
November 01, 2018
Sanofi and Regeneron have unveiled top-line data showing that two late-stage studies of Dupixent in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps (CRSwNP) met all ...
Atopic dermatitis patients to be denied NHS access to Dupixent pharmatimes
July 19, 2018
The National Institute for Health and Care Excellence has issued draft guidance rejecting Sanofi/Regeneron’s Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis.
FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma worldpharmanews
March 13, 2018
The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application of Dupixent® (dupilumab) as an add-on maintenance treatment in certain adults and adolescents (12 years of age and older) with moderate-to-s
New treatments help those with mild, moderate and severe eczema europeanpharmaceuticalreview
October 30, 2017
Crisaborole and dupilumab approved for atopic dermatitis…
Regeneron, Sanofi Announce Positive Dupilumab Topline Results September 12, 2017
Regeneron and Sanofi announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints.
Sanofi’s dupilumab joins UK’s early access scheme pharmatimes
March 15, 2017
Patients with atopic dermatitis are to get early access to Sanofi’s dupilumab before its marketing authorisation in the UK...